[PDF][PDF] Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution …

FB Van Gog, GWM Visser, R Klok… - Journal of Nuclear …, 1996 - Soc Nuclear Med
For effective adjuvant therapy, it can be anticipatedthat all tumor deposits, predominantly
small tumor nodules, should be efficiently targeted. Rhenium-l 86 seems to be a suitable …

[PDF][PDF] Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol

GWM Visser, M Gerretsen, JDM Herscheid… - Journal of Nuclear …, 1993 - Soc Nuclear Med
Radio-Nuclide-Center(RNC), Free University; and Depamnent of Otolwyngolo@ j/Head and
Neck Surgery, Free University Hospita!@ Ainsterdam@ The Netherlands further …

High dose rhenium‐186‐labeling of monoclonal antibodies for clinical application: Pitfalls and solutions

FB Gog, GWM Visser, JWG Stroomer… - … Journal of the …, 1997 - Wiley Online Library
Abstract BACKGROUND Rhenium‐186 (186Re) has ideal properties for adjuvant
radioimmunotherapy (RIT). However, the lack of suitable methods for high dose 186Re …

[CITATION][C] Radioimmunotherapy of cancer: arming the missiles

DM Goldenberg, GL Griffiths - Journal of Nuclear Medicine, 1992 - Soc Nuclear Med
100— 600mCi of †86Reused in this work are equivalent to 40— 240@ ig (2— 13 x l0@
mol) of †85Re/'@ Re, given the capability of the University of Missouri Research Reactor …

Investigations of directly labeling antibodies with rhenium-188.

P Winnard Jr, E Virzi, M Fogarasi… - The Quarterly Journal …, 1996 - europepmc.org
Methods for labeling antibodies with 99mTc cannot be used without modification for
radiorhenium despite the similar chemistries, in part because of a lower redox potential of …

[PDF][PDF] Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials

HB Breitz, PL Weiden, JL Vanderheyden… - Journal of Nuclear …, 1992 - Soc Nuclear Med
Therapy (no. of pts): None or antimetabo 6 17lites onlyRadiation ±antime 3
6tabolitesIntensive chemo ±6 8radiation and MTD of) ssRe@ labeledintact NR-LU-10, and …

[PDF][PDF] Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials

HB Breitz, DR Fisher, PL Weiden… - Journal of Nuclear …, 1993 - Soc Nuclear Med
METhODS Patients with refractoiy carcinomas were studied if their tu mors localized the@
†œTc-immunoconjugate (11). In general, â€@ Re-immunoconjugatewas …

[PDF][PDF] Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer

M Juweid, RM Sharkey, LC Swayne… - Journal of Nuclear …, 1998 - Soc Nuclear Med
The biodistribution, pharmacokinetics and dosimetry of^ Re labeled MN-14, an IgG anti-
carcinoembryonic antigen monoclonal antibody (MAb), were assessed in patients in …

188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology

N Iznaga-Escobar - Nuclear medicine and biology, 1998 - Elsevier
The increased interest in the availability of radionuclides for therapy has resulted from the
recent success and potential importance of radiolabeled antibodies for both diagnosis and …

[PDF][PDF] Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation

E John, ML Thakur, J DeFulvio… - Journal of Nuclear …, 1993 - Soc Nuclear Med
Rhenium-186-Labeled Monoclonal Antibodies for Page 1 Several attempts have been made to
label Mabs with â€86Re.Quadri and Wessels have reported 5%—18%yields using c-DTPA as …